GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (OTCPK:PHGUF) » Definitions » Inventories, Inventories Adjustments

PHGUF (Pharming Group) Inventories, Inventories Adjustments : $0.0 Mil (As of Mar. 2025)


View and export this data going back to . Start your Free Trial

What is Pharming Group Inventories, Inventories Adjustments?

Pharming Group's Inventories, Inventories Adjustments for the quarter that ended in Mar. 2025 was $0.0 Mil.


Pharming Group Inventories, Inventories Adjustments Historical Data

The historical data trend for Pharming Group's Inventories, Inventories Adjustments can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharming Group Inventories, Inventories Adjustments Chart

Pharming Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Inventories, Inventories Adjustments
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Pharming Group Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Inventories, Inventories Adjustments Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Pharming Group Inventories, Inventories Adjustments Calculation

Inventories, Inventories Adjustments represents certain charges made in the current period in inventory resulting from breakage, spoilage, employee theft and shoplifting, etc.


Pharming Group Business Description

Industry
Address
Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.